France Sets Precedent With Off-Label Avastin Move

True to its word, the French health ministry has announced that Roche's anticancer Avastin (bevacizumab) will be reimbursed for the off-label treatment of wet AMD as of Sept. 1, 2015. In doing so, the ministry is setting a precedent by encouraging the use of a drug for an unapproved indication for purely financial reasons.